A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
复制标题
13-顺式视黄酸加干扰素 α-2a 治疗晚期阴茎癌的 II 期研究：东部肿瘤合作组研究 (E3893)。
DOI：
10.1081/cnv-120016402
复制
发表时间：
2003
影响因子：
2.4
通讯作者：
Loehrer,PatrickJ
中科院分区：
文献类型：
--
作者：
Skeel,RolandT;Huang,Jie;Manola,Judith;Wilding,George;Dreicer,Robert;Walker,Paul;Muggia,Franco;Crawford,EDavid;Dutcher,JaniceP;Loehrer,PatrickJ
Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than1/2% of all male malignancies. Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13-cRA and IFN α-2a in carcinoma of the penis.Materials and Methods. Eighteen ambulatory patients with surgically unresectable, recurrent, and/or metastatic squamous cell carcinoma of the penis were treated with IFN α-2a, 3 MU/day administered subcutaneously and 13-cRA, l mg/kg orally daily for at least eight weeks, unless intolerable toxicity occurred.Results. One patient was ineligible; one patient withdrew prior to treatment. Among the 16 eligible, treated patients, there was one complete response. Fourteen patients had progressive disease as their only treatment effect. Two patients were unevaluable for tumor response because they had no follow-up tumor measurements. No unexpected treatment-related toxicities were found on study. The only common form of grade 3 toxicity was hypertriglyceridemia found in eight of the 17 patients (47%). No toxicities above grade 3 were observed.Conclusion. In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN α-2a has low efficacy in advanced carcinoma of the penis.
